News Story: Full Text
Sponsored By
NovoCure Trial
Please Click On The Above Banner For More Details
Braintumor Website

 

Additive homeopathy in cancer patients: Retrospective survival data from a homeopathic outpatient unit at the Medical University of Vienna.

Al's Comment:

This is a perfect example of how you can use statistics incorrectly to make anything look good.  The inclusion group was defined as patients who had at least 3 homeopathic consults in 4 years.  If you take any group of cancer patients and only count those that lived 4 years, of course they are going to show better results.  This doesn't capture those for whom the treatment did not work.


Posted on: 04/16/2014

Complement Ther Med. 2014 Apr;22(2):320-32. doi: 10.1016/j.ctim.2013.12.014. Epub 2014 Jan 8.
Additive homeopathy in cancer patients: Retrospective survival data from a homeopathic outpatient unit at the Medical University of Vienna.
Gaertner K1, Müllner M2, Friehs H2, Schuster E 3, Marosi C2, Muchitsch I4, Frass M5, Kaye AD6.
Author information: 
1Medical University Vienna, Department of Medicine I, Clinical Division of Oncology, Waehringer Guertel 18-20, 1090 Vienna, Austria; Institute of Complementary Medicine, Medical University Bern, Inselspital, 3010 Bern, Switzerland.
2Medical University Vienna, Department of Medicine I, Clinical Division of Oncology, Waehringer Guertel 18-20, 1090 Vienna, Austria.
3Medical University of Vienna, Center for Medical Statistics, Informatics, and Intelligent Systems, Vienna, Austria.
4Austrian Chamber of Pharmacists, Department Vienna, Austria.
5Medical University Vienna, Department of Medicine I, Clinical Division of Oncology, Waehringer Guertel 18-20, 1090 Vienna, Austria; WissHom (Scientific Society for Homeopathy), Köthen, Germany(1).
6Department of Anesthesiology and Department of Pharmacology, Louisiana State University School of Medicine Health Sciences Center, New Orleans, LA, United States. Electronic address: akaye@lsuhsc.edu.
 
Abstract
BACKGROUND: 
Current literature suggests a positive influence of additive classical homeopathy on global health and well-being in cancer patients. Besides encouraging case reports, there is little if any research on long-term survival of patients who obtain homeopathic care during cancer treatment.
 
DESIGN: 
Data from cancer patients who had undergone homeopathic treatment complementary to conventional anti-cancer treatment at the Outpatient Unit for Homeopathy in Malignant Diseases, Medical University Vienna, Department of Medicine I, Vienna, Austria, were collected, described and a retrospective subgroup-analysis with regard to survival time was performed. Patient inclusion criteria were at least three homeopathic consultations, fatal prognosis of disease, quantitative and qualitative description of patient characteristics, and survival time.
 
RESULTS: 
In four years, a total of 538 patients were recorded to have visited the Outpatient Unit Homeopathy in Malignant Diseases, Medical University Vienna, Department of Medicine I, Vienna, Austria. 62.8% of them were women, and nearly 20% had breast cancer. From the 53.7% (n=287) who had undergone at least three homeopathic consultations within four years, 18.7% (n=54) fulfilled inclusion criteria for survival analysis. The surveyed neoplasms were glioblastoma, lung, cholangiocellular and pancreatic carcinomas, metastasized sarcoma, and renal cell carcinoma. Median overall survival was compared to expert expectations of survival outcomes by specific cancer type and was prolonged across observed cancer entities (p<0.001).
 
CONCLUSION: 
Extended survival time in this sample of cancer patients with fatal prognosis but additive homeopathic treatment is interesting. However, findings are based on a small sample, and with only limited data available about patient and treatment characteristics. The relationship between homeopathic treatment and survival time requires prospective investigation in larger samples possibly using matched-pair control analysis or randomized trials.
 
Copyright © 2014 Elsevier Ltd. All rights reserved.
 
 PMID: 24731904 [PubMed - in process] 
 

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740